MedPath

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

Phase 2
Withdrawn
Conditions
Opioid-Related Disorders
Heroin Dependence
Registration Number
NCT00000329
Lead Sponsor
University of Colorado, Denver
Brief Summary

The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxone maintained volunteers

Detailed Description

Ongoing study - results not available at this time

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use.

Read More
Exclusion Criteria

Individuals with evidence of anti active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Drug/Money Preferences
Subjective dose estimate
Observed withdrawal rating
Opioid agonist rating
Opioid antagonist rating
Analog rating scale for drug effects
Pupil diameter
Drug effect characteristics
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Colorado Health Sciences Center

🇺🇸

Denver, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath